Why Protara Therapeutics, Inc.’s (TARA) Stock Is Up 5.19%
As of Tuesday, November 03, Protara Therapeutics, Inc.’s TARA share price has surged by 5.19%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company’s lead program is TARA-002, an investigational cell therapy, which is in phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.
Commentary & Analysis
Why Protara Therapeutics, Inc.’s (TARA) Stock Is Down 5.94%
As of Friday, October 23, Protara Therapeutics, Inc.’s TARA share price has dipped by 5.94%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Protara Therapeutics, Inc.’s (TARA) Stock Is Up 6.65%
As of Tuesday, October 20, Protara Therapeutics, Inc.’s TARA share price has surged by 6.65%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Protara Therapeutics, Inc.’s (TARA) Stock Is Down 6.54%
As of Wednesday, September 30, Protara Therapeutics, Inc.’s TARA share price has dipped by 6.54%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Protara Therapeutics, Inc.’s (TARA) Stock Is Down 5.79%
As of Thursday, September 24, Protara Therapeutics, Inc.’s TARA share price has dipped by 5.79%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | TARA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $134.7 | $219.9 | 25% |
|
| Shares Out (Mil) | 62.9 | 54.1 | 53% |
|
| Institutional Ownership | 97.8% | 92.9% | 75% |
|
| Float (Mil) | 54.9 | 41.4 | 48% |
|
| Beta | na | 0.95 | na |
|
| Avg Daily Volume (000s) | 782 | 522 | 64% |
|
| Price Change (52-week) |
(48.7%) | 44.7% | 21% |
|
| Growth | TARA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | (11.0%) | (10.1%) | 28% |
|
| EPS (5yr) | 22.2% | 15.8% | 72 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (16.1%) | (15.7%) | 45% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 6 | 6 | 7 | |
| Current EPS | ($0.363) | ($1.393) | ($1.691) | |
| Month Ago EPS | ($0.363) | ($1.393) | ($1.691) | |
| # Rev Up | 1 | 1 | 0 | |
| # Rev Down | 0 | 0 | 1 | |
| Three Months Ago EPS | ($0.331) | ($1.388) | ($1.644) | |
| Year/Year Chg | 3.7% | 3.9% | (39.4%) | |
| Financials | TARA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($78) | ($44) | 13% |
|
| EPS (TTM) | ($1.379) | ($1.500) | 18% |
|
| Operating Cash Flow (TTM) (Mil) | ($72) | ($35) | 8% |
|
| Net Cash Flow (TTM) (Mil) | $13 | $0 | 59% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $4 | 17% |
|
| Enterprise Value (Q1) (Mil) | ($15) | $166 | 2% |
|
| Valuation | TARA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.97 | 2.06 | 25% |
|
| P/E | na | 16.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | TARA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.3% | na |
|
| Net Margin | na | (61.0%) | na |
|
| ROA | (52.1%) | (47.5%) | 11% |
|
| ROE | (57.4%) | (52.7%) | 14% |
|
| Liabilities to Assets | 9.9% | 29.6% | 6% |
|
| F-Score | 2 | 3 | 7% |
|
Protara Therapeutics, Inc. did not pass any screens on 11/6/2026.
